Advanced Cell Technology Analyst Report; Shareholder Value Likely to Continue to Erode for the Foreseeable Future by …

NEW YORK, July 7, 2014 /PRNewswire/ --Advanced Cell Technology, Inc. (OTCQB: ACTC) is a biotechnology company focused on developing and commercializing human pluripotent stem cell technology in the field of regenerative medicine. The company is currently conducting clinical trials for treating dry age-related macular degeneration (AMD) and Stargardt's macular degeneration (SMD), as well as several clinical and preclinical programs for other ocular therapies. Outside of ophthalmology, ACTC also has a preclinical development pipeline focused on autoimmune diseases, inflammatory diseases and wound healing. The company's intellectual property portfolio includes pluripotent human embryonic stem cells (hESCs), induced pluripotent stem cells (iPSCs), and other cell therapy research programs.

As the worldwide population has continued to age, so too has the need for regenerative medicine. In fact, by 2050, the number of people in the world over the age of 65 is expected to rise to 1.5 billion nearly triple the amount today. Unsurprisingly, as this demographic shift occurs over the next 35 years, health care expenditures are projected to increase rapidly as well. For example, in the US, the share of GDP devoted to healthcare is estimated to reach 34% by 2040 from about 18% just a few years ago. Considering the majority of treatments for chronic and/or life-threatening diseases that are available today only treat symptoms rather than offer a cure for the underlying cause, regenerative medicine such as the stem cell therapies being developed by ACTC are aimed at addressing this unmet and growing need.

Macular degeneration (i.e. age-related macular degeneration, or AMD) is a medical condition that results in a loss of vision in the center of the visual field (the macula) because of damage to the retina. This indication is the leading cause of blindness and visual impairment in adults over fifty years of age. Currently, it is estimated that there are approximately 30 million people worldwide who suffer from AMD ranging from early-stage to late-stage (i.e. legal blindness), with an estimated market size of around $30 billion. Further, in an article in the journal, Lancet projected that the number of people globally with AMD will be 196 million in 2020, growing to 288 million by 2040.

A full in-depth analyst report on ACTC that includes risk factors, industry review, financial position, potential revenues, review of current business model, competition breakdown, analyst summary, and recommendation can be viewed by using the following link at no cost:

http://bit.ly/-ACTC-AnalystReport

Copy and paste to browser may be required.

FORWARD-LOOKING DISCLAIMER

This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. Research report provided for informational purposes. This document, article or report is written and authored by Michael Maggi, Chartered Financial Analyst. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

Read the original:
Advanced Cell Technology Analyst Report; Shareholder Value Likely to Continue to Erode for the Foreseeable Future by ...